Press Releases
- Jul 26, 2017First Generic Prequalification for Sofosbuvir Tablets
- Jul 19, 2017These Data, Combined with Positive Results from Two Phase 3 Efficacy Studies, Support NDA Filing Planned for Fourth Quarter of 2017
- Jul 13, 2017Vote Marks First Proposed Biosimilar Trastuzumab to be Recommended by the Committee
- Jun 10, 2017Data Show Comparable Efficacy, Safety and Immunogenicity to Lantus® in Type 1 and Type 2 Diabetes Patients
- Jun 2, 2017
- Jun 2, 2017
- May 23, 2017Presentations Review Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies; Report Prevalence of COPD Patients with Low Peak Inspiratory Flow Rate in Ongoing 12-Month Phase 3 Safety Trial
- May 17, 2017Presentations Will Include Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies
- May 16, 2017
- May 1, 2017Directors Douglas Leech, Joseph Maroon and Rodney Piatt to Retire from Board
- Mar 29, 2017
- Mar 20, 2017- TLE400 is a fixed-dose combination containing Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg -
- Mar 13, 2017
- Mar 10, 2017
